Internship

Recombinant Mammalian MSAT USP

Updated on 12/5/2024

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Biotechnology
Healthcare

No H1B Sponsorship

Framingham, MA, USA

Must be able to relocate to Framingham, MA and work 40 hours/week, Monday-Friday.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Python
PowerPoint/Keynote/Slides
Requirements
  • Currently pursuing a Bachelor's or Master's degree in Computational Science, Bioengineering, Chemical Engineering, Biotechnology, Biochemistry or related field at an accredited college or university with the expectation that you will complete your current degree by the Spring of 2027
  • Must be enrolled in school the semester following your co-op with Sanofi
  • Must be able to relocate to the office location and work 40hrs/week, Monday-Friday, for the full duration of the co-op
  • Must have permanent US work authorization
  • Hands-on experience in mammalian cell culture/aseptic technique, and cell biology techniques
  • Experience with Python coding
  • Basic understanding of general concepts of cell biology, biochemistry, and laboratory procedures
  • Ability to work in Biosafety Level 2 environment and follow lab safety procedures
  • Proficiency in Microsoft Office software (excel, PowerPoint, word)
  • Excellent communication skills, written and verbal; able to effectively communicate with supervisor and team members
  • Highly organized with a keen attention to details
Responsibilities
  • Work on an MSAT development project, to include execution of cell culture bioreactor operations and analytical equipment such as amino acid analyzer and Raman spectroscopy, etc.
  • In particular, in-silico simulations and the coding of metabolic flux analysis are used to quantify cell metabolism
  • Update the team during regular meeting and give a presentation at the end of the projects

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse pipeline of new products. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Stage

IPO

Total Funding

$2B

Headquarters

Paris, France

Founded

1973

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven Muse tool can reduce clinical trial timelines and costs.
  • Dupixent's potential approval for chronic urticaria could expand Sanofi's market share.
  • Investment in SureChill aligns with sustainability trends and improves vaccine distribution.

What critics are saying

  • Muse's adoption may face privacy concerns and regulatory scrutiny.
  • ZT-01 trial may not yield expected returns for Sanofi's diabetes investment.

What makes Sanofi unique

  • Sanofi's collaboration with OpenAI on Muse enhances patient recruitment in clinical trials.
  • Dupixent's approval for eosinophilic esophagitis in children opens new pediatric markets.
  • Investment in Orano Med positions Sanofi in innovative radioligand cancer therapies.

Help us improve and share your feedback! Did you find this helpful?